In the aftermath of Hurricane Harvey, our hearts go out to the many people impacted by the storm and flooding, particularly those in our cystic fibrosis community.
Site Search
Positive results from a study of ivacaftor (Kalydeco®) in children ages 1 to 2 were announced today.
The draft bill, crafted by the Senate Health, Education, Labor, and Pensions (HELP) Committee, aims to bring stability to the health insurance marketplaces.
Today, the U.S. Senate released its version of the health care reform bill, titled the Better Care Reconciliation Act, and in response, the Cystic Fibrosis Foundation affirmed its opposition to the legislation.
Two Phase 3 clinical trials of tezacaftor (VX-661) in combination with ivacaftor (Kalydeco®) showed positive results, Vertex Pharmaceuticals announced today.
New data show positive results in individuals with a single F508del mutation as well as people with two copies of F508del and support continued development of triple combination therapies.
The Cystic Fibrosis Foundation's Greater New York Chapter recently recognized leading journalist Scott Pelley at the 14th annual Breath of Life Gala for his unwavering dedication to those living with CF.
The Institute for Clinical and Economic Review (ICER) is developing an assessment of the clinical effectiveness and value of lumacaftor/ivacaftor (Orkambi®) and ivacaftor/tezacaftor (VX-661). The Foundation is sharing input throughout the process to help incorporate the patient and clinical perspective.
The U.S. House of Representatives has passed the American Health Care Act (AHCA), legislation that fails to adequately protect people living with cystic fibrosis.
The Cystic Fibrosis Foundation presented four individuals with awards at the 2018 Volunteer Leadership Conference (VLC). The awards given were the Tomorrow's Leader Award, the Jena Award, the Alex Award, and the Dream Big Award.